Current concepts in mild cognitive impairment
Current concepts in mild cognitive impairment
复制标题
DOI：
10.1001/archneur.58.12.1985
复制
发表时间：
2001-12-01
影响因子：
--
通讯作者：
Winblad, B
中科院分区：
文献类型：
--
作者：
Petersen, RC;Doody, R;Winblad, B
衰老和痴呆领域的重点是认知障碍最早阶段的特征。最近的研究发现，正常衰老和阿尔茨海默病 (AD) 之间的认知变化存在一种过渡状态，称为轻度认知障碍 (MCI)。轻度认知障碍是指介于正常衰老和 AD 之间的临床状况，其中人们经历的记忆丧失程度比人们预期的年龄更大，但他们不符合目前公认的临床上可能的 AD 标准。当对这些人进行纵向观察时，与年龄匹配的健康个体相比，他们进展为临床上可能的 AD 的速度要快得多。因此，这种情况已被认为适合可能的治疗干预，并且多项多中心国际治疗试验正在进行中。由于这是一个人们非常感兴趣的话题，来自世界各地的神经学、精神病学、老年病学、神经心理学、神经影像学、神经病理学、临床试验和伦理学领域的一组老龄化和MCI专家聚集在一起，总结MCI领域的现状。参与者回顾了有关衰老和 MCI 的世界科学文献，并总结了有关 MCI 的现有证据的各个主题。这些受试者的诊断标准和临床结果可在文献中找到。轻度认知障碍被认为是发展为临床上可能的 AD 的高风险病症。认识到该术语使用的异质性，并建议进行细分。虽然目前没有推荐针对 MCI 的治疗方法，但有关潜在疗法的临床试验正在进行中。就 MCI 受试者的诊断和管理中的伦理问题提出了建议。
The field of aging and dementia is focusing on the characterization of the earliest stages of cognitive impairment. Recent research has identified a transitional state between the cognitive changes of normal aging and Alzheimer's disease (AD), known as mild cognitive impairment (MCI). Mild cognitive impairment refers to the clinical condition between normal aging and AD in which persons experience memory loss to a greater extent than one would expect for age, yet they do not meet currently accepted criteria for clinically probable AD. When these persons are observed longitudinally, they progress to clinically probable AD at a considerably accelerated rate compared with healthy age-matched individuals. Consequently, this condition has been recognized as suitable for possible therapeutic intervention, and several multicenter international treatment trials are under way. Because this is a topic of intense interest, a group of experts on aging and MCI from around the world in the fields of neurology, psychiatry, geriatrics, neuropsychology, neuroimaging, neuropathology, clinical trials, and ethics was convened to summarize the current state of the field of MCI. Participants reviewed the world scientific literature on aging and MCI and summarized the various topics with respect to available evidence on MCI. Diagnostic criteria and clinical outcomes of these subjects are available in the literature. Mild cognitive impairment is believed to be a high-risk condition for the development of clinically probable AD. Heterogeneity in the use of the term was recognized, and subclassifications were suggested. While no treatments are recommended for MCI currently, clinical trials regarding potential therapies are under way. Recommendations concerning ethical issues in the diagnosis and the management of subjects with MCI were made.